Christian Brandt, MD, Bielefeld University, Medical School, Bielefeld, Germany, talks on the need to develop new instruments to assess patient-reported outcomes (PROs) in persons with epilepsy and intellectual and developmental disabilities (IDD-E). Incorporating patient-reported quality of life measures in epilepsy research is of utmost importance, as adverse events can occur in many patients receiving anti-seizure medications. While numerous systems are in place for the assessment of PROs in the general epilepsy population, there is need to tailor these tools to fit the IDD-E population. This interview took place at the 14th European Epilepsy Congress (EEC) 2022 in Geneva, Switzerland.
Honoraria for speaking or consulting activities from Angelini/Arvelle, Eisai, Equilibre, GW Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix